Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tafolecimab and Sintilimab with Chemotherapy in Advanced NSCLC
NCT06421298Phase 2Recruiting
- Start
- May 2024
- Primary completion
- May 2027
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tafolecimab in non-small cell lung cancer (NSCLC). Primary endpoint: Progression-Free Survival at 24 months. Started May 2024; status: recruiting.
02
Drugs
tafolecimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06421298.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06421298.